Upgrade to SI Premium - Free Trial

Blackrock Broad Inv Gr 2009 (BCT)

12.54 0.00 (0.00%)

Chart
Today 6M 1Y 5Y

Latest Headlines

BriaCell Therapeutics Announces Pricing of Offering May 31, 2026 7:59 PM - Globe NewsWire BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™ May 15, 2026 7:30 AM - Globe NewsWire BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer May 14, 2026 7:30 AM - Globe NewsWire BriaCell adds Penn Medicine cancer center to phase 3 breast cancer trial May 13, 2026 7:30 AM - StreetInsider BriaCell Adds Penn Medicine’s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study May 13, 2026 7:30 AM - Globe NewsWire BriaCell enrolls over 230 patients in phase 3 breast cancer study May 12, 2026 7:30 AM - StreetInsider BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients May 12, 2026 7:30 AM - Globe NewsWire BriaCell adds NYU cancer center to phase 3 breast cancer trial May 7, 2026 7:30 AM - StreetInsider BriaCell Adds NYU Langone Health’s Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study May 7, 2026 7:30 AM - Globe NewsWire BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer May 6, 2026 7:30 AM - Globe NewsWire BriaCell Announces Six Clinical Data Presentations at ASCO 2026 April 27, 2026 7:30 AM - Globe NewsWire BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models April 21, 2026 7:30 AM - Globe NewsWire BriaCell presents cancer therapy data at 2026 AACR meeting April 20, 2026 7:31 AM - StreetInsider BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting April 20, 2026 7:30 AM - Globe NewsWire BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License March 31, 2026 4:05 PM - Globe NewsWire Full Article List